文献速递间质性肺疾病

定量CT成像在进展性肺纤维化中的临床效用与有意义阈值定义

Quantitative CT Imaging in Progressive Pulmonary Fibrosis: Clinical Usefulness and Meaningful Threshold Definition.
PubMed 文献 · Chest · 2025-12-06

本研究纳入476例非IPF纤维化间质性肺疾病患者,通过深度学习定量CT计算纤维化评分(FS),以1年FVC绝对变化为锚定确定最小临床重要差异(MCID)。1年FS变化MCID为2.24%,6个月为1.34%;超过1年MCID与更差的无移植生存独立相关(校正HR 3.01,95%CI 2.19-4.14),且可在PPF标准不一致的患者中提供额外风险分层。

要点

  • 非IPF纤维化ILD患者1年FS变化MCID为2.24%,6个月为1.34%。
  • 超过1年MCID与更差无移植生存独立相关(校正HR 3.01)。
  • 定量CT进展可在PPF评估不一致时增强风险分层。

核心结论

  • 基于1年FS变化的定量CT进展性肺纤维化定义在非IPF纤维化ILD患者中具有预后价值,并可在PPF评估不一致的患者中增强风险分层。

研究设计与样本

  • 回顾性研究纳入476例非IPF纤维化ILD患者,均在基线和1年随访时接受容积CT成像。
  • 采用基于深度学习的定量CT算法计算纤维化评分(FS),并以锚定法参照1年FVC绝对变化确定MCID。

主要发现

  • 1年FS变化MCID为2.24%,6个月MCID为1.34%。
  • 超过1年MCID与更差无移植生存独立相关(校正HR 3.01;95%CI 2.19-4.14)。
  • 定量CT进展可在视觉进展不一致等PPF标准不一致的患者中提供额外风险分层(P = .02)。
  • 视觉与定量CT均进展的患者结局差于仅视觉进展者(P < .001)。
  • FS变化超过6个月MCID亦与更差结局相关(校正HR 2.82;95%CI 1.57-5.04)。

关键数值与推荐

  • 1年FS变化MCID为2.24%,6个月FS变化MCID为1.34%。
  • 超过1年MCID预测更差无移植生存的校正HR为3.01(95%CI 2.19-4.14)。
  • 超过6个月MCID预测更差结局的校正HR为2.82(95%CI 1.57-5.04)。

临床怎么用

  • 可利用定量CT计算的FS年变化(阈值2.24%)辅助定义非IPF纤维化ILD的进展性肺纤维化。
  • 在PPF标准评估不一致时,定量CT进展信息可帮助进一步风险分层。

局限性

  • 本研究为回顾性设计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although quantitative CT imaging offers objective evaluation of radiologic progression in non-idiopathic pulmonary fibrosis (IPF) fibrosing interstitial lung disease (ILD), clinically meaningful thresholds for defining progressive pulmonary fibrosis (PPF) remain unclear. RESEARCH QUESTION: What are the minimal clinically important differences (MCIDs) in quantitative CT imaging-based fibrosis score (FS) changes over 1 year and 6 months, and do these thresholds predict outcomes and enhance risk stratification in defining PPF among patients with non-IPF fibrosing ILD? STUDY DESIGN AND METHODS: This retrospective study included patients with non-IPF fibrosing ILD who underwent volumetric CT imaging at baseline and the 1-year follow-up. FS was calculated using a deep learning-based quantitative CT imaging algorithm. The MCID for FS change was determined using anchor-based methods, referencing absolute 1-year FVC change. The association of FS change MCID with transplant-free survival (TFS) and its alignment with PPF criteria were analyzed using Cox regression. Concordance between quantitative CT imaging-based and visual assessments was also assessed. RESULTS: Among 476 patients, the 1-year and 6-month MCIDs were 2.24% and 1.34%, respectively. Exceeding the 1-year MCID was independently associated with poorer TFS (adjusted hazard ratio [HR], 3.01; 95% CI, 2.19-4.14). Quantitative CT imaging-based progression provided additional risk stratification in patients with discordant PPF criteria, including those with disagreement on visual progression (P = .02). Patients with both visual and quantitative CT imaging-based progression showed worse outcomes than those with visual progression alone (P < .001). FS changes of more than the 6-month MCID were also associated with worse outcome (adjusted HR, 2.82; 95% CI, 1.57-5.04). INTERPRETATION: Quantitative CT imaging-based PPF definition using 1-year change in FS was prognostic across patients with non-IPF fibrosing ILDs and enhanced risk stratification in patients with discordant PPF assessments.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Park S, Kim MJ, Lee JH, et al. Quantitative CT Imaging in Progressive Pulmonary Fibrosis: Clinical Usefulness and Meaningful Threshold Definition. Chest. 2025. PMID: 41360185. doi:10.1016/j.chest.2025.11.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。